Position of the American Dietetic Association and Dietitians of Canada: Nutrition intervention in the care of persons with human immunodeficiency virus infection

Journal of the American Dietetic Association

Volumn 100, Issue 6, 2000, Pages 708-717

  Fields Gardner, Cade ^a   Ayoob, Keith Thomas ^b  

^a Cutting Edge   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CANADA; CHILD; COUNSELING; DIET THERAPY; EDUCATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MALE; NUTRITION; NUTRITIONAL ASSESSMENT; NUTRITIONAL DISORDER; NUTRITIONAL STATUS; PATHOGENICITY; UNITED STATES; WEIGHT REDUCTION;

ADOLESCENT; ADULT; CANADA; CHILD; COUNSELING; FEMALE; HIV; HIV INFECTIONS; HUMANS; MALE; NUTRITION ASSESSMENT; NUTRITION DISORDERS; NUTRITION PHYSIOLOGY; NUTRITIONAL STATUS; UNITED STATES; WEIGHT LOSS;

EID: 0034204378     PISSN: 00028223     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-8223(00)00207-8     Document Type: Article

References (133)

1. AIDS Epidemic Update. United Nations AIDS Project and the World Health Organization Web site. Available at: http://www.unaids.org. Accessed April 12, 2000.
2. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report. 1999;11(1):1-42. Available at: http://www.cdc.gov/nchstp/hiv_aids/ stats/hasrlink.htm. Accessed April 12, 2000.
3. Division of HIV/AIDS Surveillance, Bureau of HIV/AIDS, STD and TB. Laboratory Centre for Disease Control. HIV and AIDS in Canada: Surveillance Report to December 31, 1998. April, 1999. Health Canada, Ontario, Canada. Available at: http://www.hc-sc.gc.ca/hpb/lcdc/publicat/aids/aic1299/index.html. Accessed April 12, 2000.
4. Spaprio MF, Morton SC, McCaffrey DF, Senterfitt JW, Fleishman JA, Perlman JF, Athey LA, Keesey JW, Goldman DP, Berry SH, Bozzette SA. Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study. J Am Med Assoc. 1999;281:2305-2315.
5. Oleske JM, Rothpletz-Puglia PM, Winter H. Historical perspectives on the evolution in understanding the importance of nutritional care in pediatric HIV infection. J Nutr. 1996;126(suppl):2663S-2673S.
6. Kuhn L, Thomas PA, Singh T, Tsai WY. Long-term survival of children with human immunodeficiency virus infection in New York City: estimates from population-based surveillance data. Am J Epidemiol. 1998;147:846-854.
7. Rivera S, Briggs W, Qian D, Sattler FR. Levels of HIV RNA are quantitatively related to prior weight loss in HIV-associated wasting. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;17:411-418.
8. Semba RD, Tang AM. Micronutrients and the pathogenesis of human immunodeficiency virus infection. Br J Nutr. 1999;81:181-189.
9. Henderson RA, Saavedra JM. Nutritional considerations and management of the child with human immunodeficiency virus infection. Nutrition. 1995;11:121-128.
10. Sharpstone D, Murray C, Ross H, Phelan M, Crane R, Lepri AC, Nelson M, Gazzard B. The influence of nutritional and metabolic status on progression from asymptomatic HIV infection to AIDS-defining diagnosis. AIDS. 1999;13:1221-1226.
11. Kotler DP, Tierney AR, Wang J, Pierson RN Jr. Magnitude of body-cell-mass depletion and the timing of death from wasting in AIDS. Am J Clin Nutr. 1989;50:444-447.
12. Moore RD, Chaisson RE. Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS. 1999;13:1933-1942.
13. Strawford A, Hellerstein M. The etiology of wasting in the human immunodeficiency virus and acquired immunodeficiency syndrome. Semin Oncol. 1998;25(suppl 6):76-81.
14. Grinspoon S, CorcoranC, MillerK, BillerBM, Askari H, Wang E, Hubbard J, Anderson EJ, Basgoz N, Heller HM, Klibanski A. Body composition and endocrine function in women with acquired immunodeficiency syndrome wasting. J Clin Endocrinol Metab. 1997;82:1332-1337.
15. Mulligan K, Tai VW, Schambelan M. Cross-sectional and longitudinal evaluation of body composition in men with HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;15(1):43-38.
16. Beisel WR. Nutrition and infection. In: Linder MC, ed. Nutritional Biochemistry and Metabolism with Clinical Applications. 2nd ed. Norwalk, Conn: Appleton & Lange; 1991:507-557.
17. Ott M, Lembcke B, Fischer H, Jager R, Polat H, Geier H, Rech M, Staszeswki S, Helm EB, Caspary WF. Early changes of body composition in human immunodeficiency virus-infected patients: tetrapolar body impedance analysis indicates significant malnutrition. Am J Clin Nutr. 1993;57:15-19.
18. Kertzner RM, Goetz R, Todak G, Cooper T, Lin SH, Reddy MM, Novacenko H, Williams JB, Ehrhardt AA, Gorman JM. Cortisol levels, immune status, and mood in homosexual men with and without HIV infection. Am J Psychiatry. 1993;150:1674-1678.
19. Rivera S, Briggs W, Qian D, Sattler FR. Levels of HIV RNA are quantitatively related to prior weight loss in HIV-associated wasting. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;17:411-418.
20. Baum MK, Shor-Posner G, Lu Y, Rosner B, Sauberlich HE, Fletcher MA, Szapocznik J, Eisdorfer C, Buring JE, Hennekens CH. Micronutrients and HIV disease progression. AIDS. 1995;9:1051-1056.
21. Skurnick JH, Bogden JD, Baker H, Kemp FW, Sheffett A, Quatrrone G, Louria DB. Micronutrient profiles in HIV-1 infected heterosexual adults. J Acquir Immune Def Syndr Hum Retrovirol. 1996;12:75-83.
22. Savarino A, Pesoarmona GP, Boelaert JR. Iron metabolism and HIV infection: reciprocal interactions with potentially harmful consequences? Cell Biochem Funct. 1999;17:279-287.
23. Patrick L. Nutrients and HIV: part one - beta carotene and selenium. Altem Med Rev. 1999;4:403-413.
24. Lacey CJ, Murphy ME, Sanderson MJ, Monteiro EF, Vail A, Schorah CJ. Antioxidant micronutrients and HIV infection, Int JSTD AIDS. 1996;7(7):485-489.
25. Beisel WR. Nutrition and infection. In: MC Linder, ed. Nutritional Biochemistry and Metabolism with Clinical Applications. 2nd ed. East Norwalk, Conn: Appleton & Lange; 1991:507-511.
26. Allard JP, Aghdassi E, Chau J, Salit I, Walmsley S. Oxidative stress and plasma antioxidant micronutrients in humans with HIV infection. Am J Clin Nutr. 1998;67:143-147.
27. Kotler DP. Wasting sndrome: nutrition support in HIV infection. Acquir Immune Defic Syndr Res Hum Retrovirol. 1994;10:931-934.
28. Melchior JC. Metabolic aspects of HIV: associated wasting. Biomed Pharmacother. 1997;51:455-460.
29. Kotler DP. Human immunodeficiency virus-related wasting: malabsorption syndromes. Semin Oncol. 1998;25(suppl 6):70-75.
30. Jimenez-Exposito MJ, Garcia-Lorda P, Alonso-Villaverde C, de Virgala CM, Sola R, Masana L, Arija V, Izquierdo V, Salas-Salvado J. Effect of malabsorption on nutritional status and resting energy expenditure in HIV-infected patients. AIDS. 1998;12:1965-1972.
31. Koch J, Garcia-Shelton YL, Neal EA, Chan MF, Weaver KE, Cello JP. Steatorrhea: a common manifestation in patients with HIV/AIDS. Nutrition. 1996;12:507-510.
32. Tepper RE, Simon D, Brandt LJ, Nutrovits R, Lee MJ. Intestinal permeability in patients infected with the human immunodeficiency virus. Am J Gastroenterol. 1994;89:878-882.
33. Pernet P, Vittecoq D, Kodjo A, Randrianarisolo MH, Dumitresou L, Blondon H, Bergman JF, Giboudeau J, Aussell C. Intestinal absorption and permeability in human immunodeficiency virus-infected patients. Scand J Gastroenterol. 1999;34:29-34.
34. Sharpstone D, Neild P, Crane R, Taylor C, Hodgson C, Sherwood R, Gazzard B, Biarnason I. Small intestinal transit, absorption, and permeability in patients with AIDS with and without diarrhea. Gut. 1999;45(1):70-76.
35. Coodley GO, Loveless MO, Nelson HD, Coodley MK. Endocrine function in the HIV wasting syndrome. J Acquire Immune Defic Syndr. 1994;7:46-51.
36. Hirschfeld S. Dysregulation of growth and development in HIV-infected children. J Nutr. 1996;126(suppl):2614S-2650S.
37. Carr A, Samaras K, Thortsdottir A, Kaufman GR, Chisholm DJ, Dooper DA. Diagnosis, prediction, and natural course of HIV-1 protease inhibitor-associated lipodystophy, hyperlipidaemia, and diabetes mellitus. A cohort study. Lancet. 1999;353:2093-2099.
38. Smith K, Germain M, Decker C, Yeager J, Skelton H. Increased soft tissue in the posterior cervical and upper back area of patients on HIV-1 protease inhibitors. J Cutan Med Surg. 1999;3:211-217.
39. Safrin S, Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection. AIDS. 1999;13:2493-2505.
40. Kotler DP, Rosenbaum K, Wang J, Pierson RN. Sudies of body composition and fat distribution in HIV-infected and control subjects. J Acquir Immune Defic Syndr. 1999;20:228-237.
41. Mulligan K, Grunfeld C, Tai VW, Algren H, Pang M, Chernoff DN, Lo JC, Schambelan M. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr. 2000;23:35-43.
42. Fields-Gardner C, Thomson CA, Rhodes SS. A Clinician's Guide to Nutrition in HIV and AIDS. Chicago, III: American Dietetic Association; 1997.
43. Position of the American Dietetic Association: cost-effectiveness of medical nutrition therapy. J Am Diet Assoc. 1995;95:88-91.
44. McMahon K, Decker G, Ottery FD. Integrating proactive nutritional assessment in clinical practices to prevent complications and cost. Semin Oncol. 1998;25(suppl 6):20-27.
45. Identifying patients at risk: The American Dietetic Association's definitions for nutrition screening and nutrition assessment. J Am Diet Assoc. 1994;94:838-839.
46. Winston JA, Burns GC, Klotman PE. The human immunodeficiency virus (HIV) epidemic and HIV-associated nephropathy. Semin Nephrol. 1998;18:373-377.
47. Dube M, Johnson D, Currier J, Leedom J. Protease inhibitor-associated hypertriglyceridemia. Lancet. 1997;350:713-714.
48. Dassopoulos T, Ehrenpreis ED. Acute pancreatitis in human immunodeficiency virus-infected patients: a review. Am J Med. 1999;107:78-84.
49. Behrens G, Dejam A, Schmidt H, Balks HJ, Brabant G, Korner T, Stoll M, Schmidt RE. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors AIDS 1999;13(suppl):F63-F70.
50. Yarasheski KE, Tebas P, Sigmund C, Dagogo-Jack S, Bohrer A, Turk J, Halban PA, Cryer PE, Powderly WG. Insulin resistance in HIV protease inhibitor-associated diabetes. J Acquit Immune Defic Syndr. 1999;21:209-216.
51. Vigoureux C, Gharakhanian S, Salhi Y, Nguyen TH, Chevenne D, Capeau J, Rozenbaum W. Diabetes, insulin resisitance and dyslipidaemia and lipodystrophic HIV-infected patients on highly active antiretroviral therapy. Diabetes Metab. 1999;25:225-232.
52. Hadigan C, Miller K, Corcoran C, Anderson E, Basgoz N, Grinspoon S. Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women. J Clin Endocrinol Metab. 1999;84:1932-1937.
53. Walli R, Herfort O, Michl GM, Demant T, Jager H, Dieterle C, Bogner JR, Landgraf R, Goebel FD. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS. 1998;12(suppl):F167-F173.
54. Kotler DP, Rosenbaum K, Wang J, Pierson RN. Studies of body composition and fat distribution in HIV-infeoted and control subjects. J Acquir Immune Defic Syndr. 1999;20:228-237.
55. Engelson EE, Kotler DP, Tan YX, Wang J, Pierson RN, Heymsfield SB. Altered fat and skeletal muscle distribution in HIV-infected patients reporting increased abdominal girth. Am J Clin Nutr. 1999;69:1162-1169.
56. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 1999;353:2093-2099.
57. Yanovski JA, Miller KD, Kino T, Friedman TC, Chrousos GP, Tsigos C, Falloon J. Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy. J Clin Endocrinol Metab. 1999;84:1925-1931.
58. Renard E, Fabre J, Paris F, Reynes J, Bringer J. Syndrome of body fat redistribution in HIV-1-infected patients: relationships to cortisol and catecholamines. Clin Endocrinol. 1999;51:223-230.
59. Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystophy. Lancet. 1999;354:1112-1115.
60. Saint-Marc T, Partisani M, Poizot-Martin I, Bruno F, Rouviere O, Lang JM, Gastaut JA, Touraine JL. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS. 1999;13:1659-1667.
61. Carbonnel F, Maslo C, Beaugerie L, Carrat F, Wirbel E, Aussel C, Gobert JG, Girard PM, Gendre JP, Cosnes J, Rozenbaum. Effect of indinavir on HIV-related wasting. AIDS. 1998;12:1777-1784.
62. Silva M, Skolnik PR, Gorbach SL, Spiegelman D, Wilson IB, Fernandez-DiFranco MG, Knox TA. The effect of protease inhibitors on weight and body composition in HIV-infected patients. AIDS. 1998;12:1645-1651.
63. Nutrition Interventions Manual for Professionals Caring for Older Americans: Executive Summary. Washington, DC: Nutrition Screening Initiative; 1992.
64. Fenton M, Silverman E, Vazzo L. HIV/AIDS adult medical nutrition therapy protocol. In: Gilbreath J, Inman-Felton AE, Johnson EQ, Robinson G, Smith K, eds. Medical Nutrition Therapy Across the Continuum of Care. Chicago, III: American Dietetic Association and Morrison Health Care; 1998.
65. Heller L, Rothpletz-Puglia P, Morris V, Papthakis P. HIV/AIDS children/ adolescents medical nutrition therapy Protocol. In: Gilbreath J, Inman-Felton AE, Johnson EQ, Robinson G, Smith K, eds. Medical Nutrition Therapy Across the Continuum of Care. Chicago, III: American Dietetic Association and Morrison Health Care; 1998.
66. National Cholesterol Education Program. Available at: http:// www.nhlbi.nih.gov. Accessed April 12, 2000.
67. Vogel RA. The management of hypercholesterolemia in patients with coronary artery disease: guidelines for primary care. Clin Cornerstone. 1998;1:51-64.
68. American Diabetes Association: clinical practice recommendations 1997. Diabetes Care. 1997;20(suppl 1):S1-S70.
69. American Diabetes Association. Nutrition recommendations and principles for people with diabetes mellitus. Diabetes Care [serial online], 1000;23(suppl). Available at http://journal.diabetes.org/FullText/Supplements/ DiabetesCare/Supplement100/s43.htm. Accessed April 12, 2000.
70. Saavedra JM, Henderson RA, Perman JA, Huton N, Livingston RA, Yolken RH. Longitudinal assessment of children born to mothers with human immunodeficiency virus infection. Arch Adolescent Med. 1995;149:497-502.
71. MoKinney RE Jr, Robertson JW. Effect of human immunodeficiency virus infection on the growth of young children. Duke Pediatric AIDS Clinical Trials Unit. J Pediatr. 1993;123:579-582.
72. Weight, height, and human immunodeficiency virus infection in young children of infected mothers. The European Collaborative Study. Pediatr Infect Dis J. 1995;14:685-690.
73. Zuckerman GB, Sanchez JL, Conway EE. Neurologic complications of HIV infections in children. Pediatr Ann. 1998;27:635-639.
74. Mintz M. Neurological and developmental problems in pediatric HIV infection. J Nutr. 1996;126(suppl):2663S-267S.
75. LePage P, Msellati P, Hitimana DG, Bazubagira A, VanGoethem C, Simonon A, Karita E, Dequae-Merehadou L, Van de Perre P, Dabis F. Growth of human immunodeficiency type 1-infected and uninfected children: a prospective cohort study in Kigali, Rwanda 1988 to 1993. Pediatr Inf Dis J. 1996;15:479-485.
76. Peters VB, Rosh JR, Mugrditchian L, Birnbaum AH, Benkov KJ, Hodes DS, LeLeiko NS. Growth failure is the first expression of malnutrition in children with human immunodeficiency virus infection. Mt Sinai J Med. 1998;65:1-4.
77. Pollack H, Glasberg H, Lee E, Nirenberg A, David R, Krasinski D, Borkowsky W, Oberfield S. Impaired early growth of infants perinatally infected with human immunodeficiency virus: correlation with viral load. J Pediatr. 1997;130:915-922.
78. Miller TL, Awnetwant EL, Evans S, Morris VM, Vazquez IM, McIntosh K. Gastrostomy tube supplementation for HIV-infected children. Pediatrics. 1995;96:696-702.
79. Henderson RA, Saavedra JM, Perman JA, Hutton N, Livingston RA, Yolken RH. Effect of enterai tube feeding on growth of children with symptomatic human immunodeficiency virus infection. J Pediatr Gastroenterol Nutr. 1994;18:429-434.
80. Winter H. Gastrointestinal tract function and malnutrition in HIV-infected children. J Nutr. 1996;126(suppl):2620S-2622S.
81. Hirschfeld S. Dysregulation of growth and development in HIV-infected children. J Nutr. 1996;126(suppl):2614S-2650S.
82. Arpadi SM, Horlick MN, Wang J, Cugg P, Bamji M, Kotler DP. Body composition in prepubertal children with human immunodeficiency virus type 1 infection. Arch Pediatr Adolesc Med. 1998;152(7):688-693.
83. Heller L, Fox S, Hell KJ, Church JA. Development of an instrument to assess nutritional risk factors for children infected with human immunodeficiency virus. J Am Diet Assoc. 2000;100:323-329.
84. Rabenck L, Palmer A, Knowles JB, Seidehamel RJ, Harris CL, Merkal KL, Resser JM, Akrabawi SS. A randomized controlled trial evaluating nutrition counseling with or without oral supplementation in malnourished HIV-infected patients. J Am Diet Assoc. 1998;98:434-438.
85. Gagnon AJ, Therrien R, eds. HIV Medication Guide. V2.05. 1999. Available at: http://www.jag.ca/on/hiv. Accessed September 2, 1999.
86. Centers for Disease Control and Prevention. Food and water borne bacterial diseases. Revised March 9, 1995. Available at: http://www.cdc.gov/ ncidod/diseases/bacter/foodborn.htm. Accessed September 2, 1999.
87. Black RF. Transmission of HIV-1 in the breastfeeding process. J Am Diet Assoc. 1996;96:267-274.
88. Pronsky ZM, Fields-Gardner C. HIV Medications, Food Interactions. 1st ed. Pottstown, Pa: Food-Medication Interactions; 1998.
89. Sande MA, Gilbert DN, Moellering RC. The Sanford Guide to HIV/AIDS Therapy. 8th ed. Hyde Park, Vt: Antimicrobial Therapy;1999.
90. Position of the American Dietetic Association: medical nutrition therapy and pharmacotherapy. J Am Diet Assoc. 1999;99:227-230.
91. Shephard RJ. Exercise, immune function and HIV infection, J Sports Med Phys Fitness. 1998;38:101-110.
92. Evans WJ, Roubenoff R, Shevitz A. Exercise and the treatment of wasting: aging and human immunodeficiency virus infection. Semin Oncol. 1998; 25(suppl 6):112-122.
93. Wagner G, Rabkin J, Rabkin R. Exercise as a mediator of psychological and nutritional effects of testosterone therapy in HIV+ men. Med Sci Sports Exerc. 1998;30:811-817.
94. Haslett P, Hempstead M, Seidman C, Diakun J, Vasquez D, Freedman VH, Kaplan G. The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus. AIDS Res Hum Retroviruses. 1997; 13:1047-1054.
95. Mulligan K, Bloch AS. Energy expenditure and protein metabolism in human immunodeficiency virus infection and cancer cachexia. Semin Oncol. 1998;25(suppl 6):82-91.
96. Position of the American Dietetic Association: vitamin and mineral supplementation. J Am Diet Assoc. 1996;96:73-77.
97. Tang AM, Graham NM, Saah AJ. Effects of micronutrient intake on survival in human immunodeficiency virus type 1 infection. Am J Epidemiol. 1996;143:1244-1256.
98. Allard JP, Aghdassi E, Chau J, Tam C, Kovacs CM, Salit IE, Walmsley SL. Effects of vitamin E and C supplementation on oxidative stress and viral load in HIV-infected subjects. AIDS. 1998;12:1653-1659.
99. Position of the American Dietetic Association: food and nutrition misinformation. J Am Diet Assoc. 1995;95:705-707.
100. Calabrese C, Wenner CA, Reeves C, Turet P, Standish LJ. Treatment of human immunodeficiency virus-positive patients with complementary and alternative medicine: a survey of practitioners. J Altern Complement Med. 1998;4:281-287.
101. Maclntyre RC, Holzemer WL, Philippek M. Complementary and alternative medicine in HIV/AIDS. Part I: Issues and context. J Assoc Nurses AIDS Care. 1997;8:23-31.
102. Maclntyre RC, Holzemer WL. Complementary and alternative medicine in HIV/AIDS. Part II: selected literature review. J Assoc Nurses AIDS Care. 1997;8:25-38.
103. Grinspoon S, Corcoran C, Miller K, Wang E, Hubbard J, Schoenfeld D, Anderson E, Basgoz N, Klibanski A. Determinants of increased energy expenditure in HIV-infected women. Am J Clin Nutr. 1998;68:720-725.
104. Shevitz AH, Knox TA, Spiegelman D, Roubenoff R, Gorbach SL, Skolnik PR. Elevated resting energy expenditure among HIV-seropositive people receiving highly active antiretroviral therapy. AIDS. 1999;13:1351-1357.
105. Beau JP, Imboua-Coulibaly L. Dehydration: an important factor of mortality in human immunodeficiency virus (HIV) seropositive malnourished children. Bull Soc Pathol Exot. 1997;90:71-73.
106. Baynes RD, Cook JD. Current issues in iron deficiency. Curr Opin Hematol. 1996;3:145-149.
107. Kotler DP, Tierney AR, Culpepper-Morgan JA, Wang J, Pierson RN. Effect of home total parenteral nutrition on body composition in patients with acquired immunodeficiency syndrome. J Parenter Enteral Nufr.1990;14:454-458.
108. Henderson RA, Talusan K, Hutton N, Yolken RH, Caballero B. Whole body protein turnover in children with human immunodeficiency virus (HIV) infection. Nutrition. 1999;15:189-194.
109. Hellerstein MK. De novo lipogenesis in humans: metabolic and regulatory aspects. Eur J Clin Nutr. 1999;53(suppl 1):S53-S65.
110. Hoh R, Pelfini A, Neese RA, Chan M, Cello JP, Cope FO, Abruzzese BC, Richards EW, Courtnay K, Hellerstein MK. De novo lipogenesis predicts short-term body composition response by bioelectrical impedance analysis to oral nutritional supplements in HIV-associated wasting. Am J Clin Nutr. 1998;68:154-163.
111. Henderson RA, Saavedra JM, Perman JA, Hutton N, Livingston RA, Yolken RH. Effect of enterai tube feeding on growth of children with symptomatic human immunodeficiency virus infection. J Pediatr Gastroneterol Nutr. 1994;18:429-434.
112. Kotler DP, Rosenbaum K, Wang J, Pierson RN. Studies of body composition and fat distribution in HIV infection and control subjects. J Acquir Immune Defic Syndr Hum Retrovirol. 1999;20:228-237.
113. Strawford A, Hellerstein M. The etiology of wasting in the human immunodeficiency virus and acquired immunodeficiency syndrome. Semin Oncol. 1998;25(suppl 6):76-81.
114. Heller L. HIV-associated weight loss in pediatric patients. Clinician. 1999;17:32-39.
115. Mulligan K, Tai VW, Schambelan M. Effects of chronic growth hormone treatment on energy intake and resting energy metabolism in patients with human immunodeficiency virus-associated wasting - a clinical research center study. J Clin Endocrinol Metab. 1998;83:1542-1547.
116. Schambelan M, Mulligan K, Grunfeld C, Daar ES, LaMarca A, Kotler DP, Wang J, Bozette SA, Breitmeyer JB. Recombinant human growth hormone in patients with HIV-associated wasting. A randomized, placebo-controlled trial. Serostim Study Group. Ann Intern Med. 1996;124:873-882.
117. Miller K, Corcoran C, Armstrong C, Caramelli K, Anderson E, Cotton D, Basgoz N, Hirschhorn L, Tuomala R, Schoenfeld D, Daugherty C, Mazer N, Grinspoon S. Treansdermal testosterone administration in women with acquired immunodeficiency syndrome wasting: a pilot study. J Clin Endocrinol Metab. 1998;83:2717-2715.
118. Grinspoon S, Corcoran C, Askari H, Scheonfeld D, Wolf L, Burrows B, Walsh M, Hayden D, Parlman K, Anderson E, Basgoz N, Klibanski A. Effects of androgen administration in men with the AIDS wasting syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1998;129:18-26.
119. Saint-Marc T, Touraine JL. Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor therapy. AIDS. 1999;13:1000-1002.
120. Gold J, Batterham M. Nandrolone decanoate; use in HIV-associated lipodystrophy syndrome: a pilot study, Int J STD AIDS. 1999;10:558.
121. Wanke C, Gerrior J, Kantaros J, Coakley E, Albrecht M. Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV. AIDS. 1999;13:2099-2103.
122. Roubenoff R, Weiss L, McDermott A, Heflin T, Coutier CJ, Wood M, Gorbach S. A pilot study of exercise training to reduce trunk fat in adults with HIV-associaled fat redistribution. AIDS. 1999;13:1373-1375.
123. Wanke C. Single-agent/combination therapy of human immunodeficiency virus-related wasting. Semin Oncol. 1998;25(suppl 6):98-103.
124. Strawford A, Barbieri T, Van Loan M, Parks E, Catlin D, Barton N, Neese R, Christiansen M, King J, Hellerstein MK. Resistance exercise and supraphysiologic androgen therapyin eugonadal men with HIV-related weight loss: a randomized controlled trial. JAMA. 1999;281:1282-1290.
125. Mocroft A, Kirk O, Barton SE, Dietrich M, Proenca R, Colebunders R, Pradier C, dArminio Monforte A, Ledergerber B, Lundgren JD. Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. EuroSIDA Study Group. AIDS. 1999;13:943-950.
126. Echevarria KL, Hardin TC, Smith JA. Hyperlipidemia associated with protease inhibitor therapy. Ann Pharmacother. 1999;33:859-863.
127. Melroe NH, Kopaczewski J, Henry K, Huebsch. Intervention for hyperlipidemia associated with protease inhibitors. J Assoc Nurses AIDS Care. 1999;10:55-69.
128. Meyer L, Rabaud C, Ziegler O, May T, Drouin P. Protease inhibitors, diabetes mellitus and blood lipids. Diabetes Metab. 1998;24:547-549.
129. University of California, San Francisco. HIV InSite HIV Drug Database. Available at: http://www.arvdb.ucsf.edu. Accessed April 12, 2000.
130. AIDS Nutrition Services Alliance Web site. Available at: http:// www.aidsnutrition.org. Accessed April 12, 2000.
131. Bellesky K. What is the Ryan White CARE Act? Positive Communication. 1999;4:5-6.
132. Sarubin A. The Health Professional's Guide to Popular Dietary Supplements. Chicago, Ill: American Dietetic Association; 2000.
133. Tyler VE. The Honest Herbal: A Sensible Guide to the Use of Herbs and Related Remedies. 3rd ed. New York, NY: Pharmaceutical Products Press, 1993.